{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7"},{"groupId":"OG001","value":"0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1"},{"groupId":"OG001","value":"4.2"}]}],"title":"Marrow CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8"},{"groupId":"OG001","value":"30.3"}]}],"title":"Stable Disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.6"},{"groupId":"OG001","value":"46.8"}]}],"title":"Disease Progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"0.9"}]}],"title":"Failure due to Death"}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"description":"Hematologic response was defined as: • A complete response (CR): \\<5% myeloblasts, and normal maturation of all cell lines; Peripheral blood (PB) shows: hemoglobin \\>10 g/dL, neutrophils ≥1.0x10\\^9/L, platelets ≥100x10\\^9/dL, blasts (0%) • Partial Response (PR): same as CR bone marrow (BM) shows blasts decreased by ≥ 50% over pre-treatment but still \\> 5%; Cellularity and morphology not relevant • Marrow CR: BM: ≤ 5% myeloblasts and decrease by ≥ 50% over pre-treatment PB • Stable disease (SD): failure to achieve at least PR, but no evidence of progression for \\> 8 wks • Failure: death during treatment or disease progression • Disease Progression for those with: - Less than 5% blasts: ≥ 50% increase in blasts to \\> 5% blasts - 5%-10% blasts:≥ 50% increase to \\> 10% blasts - 10%-20% blasts:≥ 50% increase to \\> 20% blasts - 20%-30% blasts ≥ 50% increase to \\> 30% blasts Any of the following: - ≥ 50% decrease from maximum remission/response in granulocytes or platelets","groups":[{"description":"Participants received 300 mg oral azacitidine tablets daily on days 1 to 21 of each 28-day treatment cycle and BSC included and was not limited to pRBC (packed red blood cell \\[pRBC\\] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.","id":"OG000","title":"Oral Azacitidine and Best Supportive Care"},{"description":"Participants received identically matching placebo tablets QD on days 1 to 21 of each 28-day treatment cycle and BSC which included but was not limited to, pRBC and whole blood, platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and G-CSF for participants who experienced neutropenic fever/infections.","id":"OG001","title":"Placebo Plus Best Supportive Care"}],"paramType":"NUMBER","populationDescription":"Population includes participants with a CR, PR and mCR who had baseline bone marrow blasts \\> 5%. ITT population.","reportingStatus":"POSTED","timeFrame":"Response was assessed every 3 cycles; up to the data cut-off date of 25 Jan 2019; median duration of exposure to oral azacitidine was 86.0 days and 119.0 days for placebo","title":"Percentage of Participants With a Hematologic Response According to the 2006 IWG Criteria for MDS","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}